OHDSI / OncologyWG

Oncology Working Group Repository
https://ohdsi.github.io/OncologyWG
Apache License 2.0
56 stars 24 forks source link

Missing TNM concepts #636

Open gkennos opened 6 months ago

gkennos commented 6 months ago
Missing term Parent Valid because
p-8th_aJCC/UICC-N0(i-) https://athena.ohdsi.org/search-terms/terms/1635560 pN0(i-) exists in NAACCR and also in the AJCC documentation (also in the data)
p-8th_aJCC/UICC-N0(mol-) https://athena.ohdsi.org/search-terms/terms/1635560 Present in data as well as SEER docs and AJCC docs, though SNOMED term has been invalidated so validity TBC
p-8th_aJCC/UICC-Tis(LCIS) https://athena.ohdsi.org/search-terms/terms/1633920 As per (mol-)

Also true for other editions. (i-) is the most prevalent and most supported via other terms, but the others also present in standards and in the data, so direction required.

cgreich commented 6 months ago

The (i-), (i+), (mol-) and (mol+) make sense as children of N0. The DCIS/LCIS right now is part of ICDO3 (e.g. this and this). We probably don't want it twice.

gkennos commented 6 months ago

DCIS is already in the cancer modifier vocab, as well as being in the staging standard so it feels a bit inconsistent to leave LCIS out?

1635835

rtmill commented 6 months ago

@kzollove appropriately added this to the TNM task group above.

The (i-), (i+), (mol-) and (mol+) make sense as children of N0. The DCIS/LCIS right now is part of ICDO3 (e.g. this and this). We probably don't want it twice.

@cgreich I'm not seeing the overlap and consequently concern here. We're specifically referring to staging observations without the context of the related condition. Can you elaborate on why the existence of ICDO3 codes is needing to be considered here?

cgreich commented 6 months ago

@rtmill: Sure.

The problem is how to handle the "in situ" cancers. On one hand, they are early stage. On the other hand, because they are early stage, they are not visible macroscopically and therefore reported as histological findings. So, is the "in situ" a stage (and hence a Cancer Modifier Measurement) or a histology (and hence a ICDO3 Condition)? Can't have it both ways in our system.

I know the oncologists use both ways. They don't have a precise model to work with that has to adhere to the principle of one representation of fact.

There are two solutions:

The former is probably easier than the latter. But then the hierarchy won't pick them up.

Which means we kick the can down to the analyst who has to realize the duplication and do the queries appropriately. It sounds worse than it is in my opinion, because the analyst already has to realize that "metastatic disease" means looking for Metastasis and all its descendants as well as for AJCC/UICC M1 Category and all its descendants.

So, maybe yes, let's add it.